Literature DB >> 23267526

Management of acute type B aortic dissection.

G Chad Hughes1, Nicholas D Andersen, Richard L McCann.   

Abstract

Acute type B aortic dissection (identified within 2 weeks of symptom onset), as described using the Stanford classification, involves the aorta distal to the left subclavian artery and accounts for 25%-40% of all aortic dissections. The traditional treatment paradigm of medical management for uncomplicated acute type B dissection and open surgical intervention for early or late complications of type B dissection is currently undergoing a period of evolution as a result of the influence of minimally invasive thoracic endovascular aortic repair options. Thoracic endovascular repair has replaced open surgical repair as the preferred treatment for complicated acute type B dissection, and may also prove beneficial for prophylactic repair of uncomplicated acute type B dissection for high-risk patients. This review discusses the management of acute type B aortic dissection and long-term treatment considerations.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23267526     DOI: 10.1016/j.jtcvs.2012.11.078

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  13 in total

Review 1.  TEVAR for type B aortic dissection in Japan.

Authors:  Akihiko Usui
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-12-10

2.  Prognostic significance of early aortic remodeling in acute uncomplicated type B aortic dissection and intramural hematoma.

Authors:  Anna M Sailer; Patricia J Nelemans; Trevor J Hastie; Anne S Chin; Mark Huininga; Peter Chiu; Michael P Fischbein; Michael D Dake; D Craig Miller; G W Schurink; Dominik Fleischmann
Journal:  J Thorac Cardiovasc Surg       Date:  2017-05-16       Impact factor: 5.209

3.  Thoracic endovascular aortic repair versus open chest surgical repair for patients with type B aortic dissection: a systematic review and meta-analysis.

Authors:  Jianping Liu; Juan Xia; Gaowu Yan; Yongheng Zhang; Jing Ge; Lin Cao
Journal:  Ann Med       Date:  2019-10-25       Impact factor: 4.709

Review 4.  Endovascular versus open surgical repair for complicated chronic Type B aortic dissection.

Authors:  Fionnuala Jordan; Brian FitzGibbon; Edel P Kavanagh; Peter McHugh; Dave Veerasingam; Sherif Sultan; Niamh Hynes
Journal:  Cochrane Database Syst Rev       Date:  2021-12-14

5.  Endovascular management of chronic post-dissection aneurysms.

Authors:  Kyriakos Oikonomou; Athanasios Katsargyris; Wolfgang Ritter; Domenico Spinelli; Yuki Seto; Eric L Verhoeven
Journal:  Ann Cardiothorac Surg       Date:  2014-05

Review 6.  [Acute aortic syndrome].

Authors:  S Semsroth; J Dumfarth; T Schachner; M Grimm; H Domanovits
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-06       Impact factor: 0.840

7.  Use of a stent-graft and vascular occlude to treat primary and re-entry tears in a patient with a Stanford type B aortic dissection.

Authors:  Huihua Shi; Min Lu; Mier Jiang
Journal:  Rev Bras Cir Cardiovasc       Date:  2013 Oct-Dec

8.  Neutrophil to lymphocyte ratio and fibrinogen values in predicting patients with type B aortic dissection.

Authors:  Shuangshuang Li; Jin Yang; Jian Dong; Renle Guo; Sheng Chang; Hongqiao Zhu; Zhaohui Li; Jian Zhou; Zaiping Jing
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

9.  Endovascular stenting of a complicated type B aortic dissection in an 11-year-old patient: Case Report.

Authors:  Arkadiusz Kazimierczak; Paweł Rynio; Piotr Gutowski; Tomasz Jedrzejczak
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

10.  Serum amyloid a protein as a potential biomarker in predicting acute onset and association with in-hospital death in acute aortic dissection.

Authors:  Yuchen He; Changcheng Ma; Jia Xing; Shiyue Wang; Chao Ji; Yanshuo Han; Jian Zhang
Journal:  BMC Cardiovasc Disord       Date:  2019-12-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.